Here at CARB-X, we are in the fifth year of a five-year mandate to invest $480 million to support the early development of innovative products to prevent, diagnose and treat drug-resistant bacterial infections. Our remaining funds will continue to support projects in the portfolio and new projects that are currently under negotiation. We are discussing next steps with potential funders, but new CARB-X funding rounds can only come after such funding is secured.

Therefore, no new funding rounds are scheduled at this time.

Information on the web pages in the Apply section apply to past practices and may be of interest and help to understand the CARB-X process. Please note however that this information is subject to modification as we plan for potential new funding rounds in the future once additional funding is obtained by CARB-X.